Founded in 1875 in Indianapolis, Eli Lilly has grown into one of America's most valuable companies, posting $65.2B in revenue and a $1.0T market cap in FY2025.
From Indianapolis to a Trillion-Dollar Name
Eli Lilly & Co has been making medicines since 1875 — long before most of today's pharmaceutical giants existed. What started as a modest operation in Indianapolis, Indiana has become one of the most valuable enterprises in American history, with a market capitalization of $1.0 trillion. That number alone places Lilly in extraordinarily rare company.
Four Diseases, One Clear Strategy
Lilly is a drug company with a sharp focus on four therapeutic areas: neuroscience, cardiometabolic disease, cancer, and immunology. Its portfolio spans some of the most consequential medicines in recent memory.
Key products include: - Cancer: Verzenio, Jaypirca - Cardiometabolic: Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, Humulin - Immunology: Taltz, Olumiant
Revenue Growth That Redefines Scale
Lilly posted revenue of $65.2 billion in FY2025. More striking than the number itself is the trajectory behind it: revenue grew 130% between FY2021 and FY2025, more than doubling in just four years. That kind of expansion is rare for any established company, let alone one celebrating its 150th year in business.
Margins That Turn Heads
A gross margin of 83.0% reflects how efficiently Lilly converts sales into earnings before operating costs — a figure made possible by high-value drug portfolios where the real investment is research, not raw materials.
Net income came in at $20.6 billion for FY2025, yielding a net margin of 31.7%. In plain terms, for roughly every three dollars Lilly brings in, it keeps nearly one as profit. That level of profitability exceeds most industries — manufacturing, retail, and much of technology included.
What the Market Is Saying
Lilly trades on the New York Stock Exchange under the ticker LLY, with a recent share price of $1,208.12 and a market capitalization of $1.0 trillion. Its price-to-earnings ratio of 52.6 signals that investors are pricing in expectations of continued strong performance.
A Dividend, Too
Trading near its 52-week high, Lilly also pays a dividend yielding about 0.57% annually — modest, but consistent with a company that clearly reinvests heavily in its own growth engine.
A Solid Balance Sheet
Total assets stand at $112.5 billion, giving the company a substantial financial foundation to support ongoing research, manufacturing expansion, and pipeline development. That asset base matters in an industry where drug development timelines are long and capital-intensive.
50,000 Employees, One Hometown
Roughly 50,000 employees work for Lilly worldwide, all directed from its longtime home in Indianapolis, Indiana. The company has been publicly traded since July 1970, giving it more than five decades of market history alongside its century and a half as a going concern.
Why This Moment Matters
The 130% revenue growth over four years is not an accident of accounting — it reflects the enormous demand for Lilly's cardiometabolic portfolio and the broader global need those medicines address. With $65.2 billion in revenue, $20.6 billion in net income, and a trillion-dollar market cap, Eli Lilly now stands among the most consequential companies in American industry, by almost any measure.
This article is factual reporting drawn from public filings and market data, and is not investment advice.
